Please login to the form below

Not currently logged in
Email:
Password:

Cosentyx

This page shows the latest Cosentyx news and features for those working in and with pharma, biotech and healthcare.

Skyrizi, Rinvoq help AbbVie weather Humira slowdown

Skyrizi, Rinvoq help AbbVie weather Humira slowdown

The growth came despite another strong quarter for Novartis’ IL-17 inhibitor Cosentyx (secukinumab) in psoriasis – currently leading the charge among a new generation of biologic therapies for the skin disorder

Latest news

More from news
Approximately 31 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    Hudson had a distinguished career at Novartis, presiding over the launches and roll-outs of psoriasis blockbuster Cosentyx (secukinumab), spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec) and heart failure therapy

  • Pharma: in search of the sustainable ‘win win’ with the NHS Pharma: in search of the sustainable ‘win win’ with the NHS

    An Outcomes Guarantee model - Cosentyx promise. Among the many initiatives Novartis is working on with the NHS is ‘The Cosentyx Promise’. ... Cosentyx is the company's psoriasis treatment, and Novartis supplies the drug with an outcomes guarantee.

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    costs. It was then backed with a ‘no response-no payment’ contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • The good, the bad and the ugly The good, the bad and the ugly

    Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic arthritis treatment - Cosentyx - while GSK’s lupus therapy, Benlysta, has helped it increase immunology revenues by almost 45%.”.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Maker Projects

    Our clients include: The NHS NWEH Cancer Research Cosentyx / Novartis Brilinta / AstraZeneca Port of Call We have branches in Manchester and London - to find out more: www.makerprojects.co.

  • 90TEN nominated for five Communiqué Awards

    Year. 90TEN’s work with Novartis on the global launch of Cosentyx is nominated for Excellence in Media Relations.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics